Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Pijl H, Charehbili A, van de Ven S, Smit VTHBM, Meershoek-Klein Kranenbarg E, Heijns JB, van Warmerdam LJC, Kessels LW, Dercksen MW, Pepels MJAE, van Laarhoven HWM, Vriens BEPJ, Putter H, Fiocco M, Liefers GJ, van der Hoeven JJM, Nortier JWR, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: van der hoeven jjm, van warmerdam ljc, van laarhoven hwm, van de ven s. Breast Cancer Res. 2019 Aug 28;21(1):97. doi: 10.1186/s13058-019-1180-6. Breast Cancer Res. 2019. PMID: 31455425 Free PMC article.
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B, Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Charehbili A, et al. Among authors: van laarhoven hw, van warmerdam lj, van de ven s, van de velde cj, van leeuwen stok ae. Ann Oncol. 2014 May;25(5):998-1004. doi: 10.1093/annonc/mdu102. Epub 2014 Feb 27. Ann Oncol. 2014. PMID: 24585721 Free article. Clinical Trial.
Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S. Onstenk W, et al. Among authors: van laarhoven hw, van de ven s, van de velde cj. Mol Cancer Ther. 2015 Mar;14(3):821-7. doi: 10.1158/1535-7163.MCT-14-0653. Epub 2014 Dec 31. Mol Cancer Ther. 2015. PMID: 25552367 Clinical Trial.
Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group. de Groot S, et al. Among authors: van laarhoven hw, van de ven s, van der straaten t, van der hoeven jj. Breast Cancer Res. 2016 Jan 6;18(1):3. doi: 10.1186/s13058-015-0663-3. Breast Cancer Res. 2016. PMID: 26738606 Free PMC article. Clinical Trial.
Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac.
Eijkelenkamp H, Grimbergen G, Daamen LA, Heerkens HD, van de Ven S, Mook S, Meijer GJ, Molenaar IQ, van Santvoort HC, Paulson E, Erickson BA, Verkooijen HM, Hall WA, Intven MPW. Eijkelenkamp H, et al. Among authors: van de ven s. Front Oncol. 2023 Oct 3;13:1040673. doi: 10.3389/fonc.2023.1040673. eCollection 2023. Front Oncol. 2023. PMID: 37854684 Free PMC article.
Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort.
van de Ven S, van den Bongard D, Pielkenrood B, Kasperts N, Eppinga W, Peters M, Verkooijen H, van der Velden J. van de Ven S, et al. Among authors: van den bongard d, van der velden j. Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):39-47. doi: 10.1016/j.ijrobp.2019.12.041. Epub 2020 Jan 30. Int J Radiat Oncol Biol Phys. 2020. PMID: 32007565 Clinical Trial.
Clinical implementation and feasibility of long-course fractionated MR-guided chemoradiotherapy for patients with esophageal cancer: An R-IDEAL stage 1b/2a evaluation of technical innovation.
Boekhoff MR, Bouwmans R, Doornaert PAH, Intven MPW, Lagendijk JJW, van Lier ALHMW, Rasing MJA, van de Ven S, Meijer GJ, Mook S. Boekhoff MR, et al. Among authors: van lier alhmw, van de ven s. Clin Transl Radiat Oncol. 2022 Mar 17;34:82-89. doi: 10.1016/j.ctro.2022.03.008. eCollection 2022 May. Clin Transl Radiat Oncol. 2022. PMID: 35372703 Free PMC article.
66 results